Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity news is a peerless national resource for those of us who really want to stay on top the very latest news in healthcare from incumbents to startups. ”

Elliot Menschik, DreamIt Ventures partner; Venturef0rth founder; Penn professor


Sign up for our daily newsletter


Stryker announces FDA approval of clot removal device to treat ischemic stroke

10:38 am by | 0 Comments

Covidien FDA approval

Stryker announced Monday that the U.S. Food and Drug Administration has cleared a clot removal device to treat patients experiencing acute ischemic stroke.

Ischemic strokes are caused by blocked arteries and constitute the overwhelming majority of strokes, according to the Mayo Clinic.

The Trevo Pro Retrieval System performed better than Merci Retrieval, made by Concentric Medical, now part of Stryker, in getting blood flowing back to the brain, which is critical for stroke patients, according to a company news release. The clinical trial that measured the safety and efficacy of the Trevo system also showed that patients treated with it had shorter hospital stays.

Advertisement

“As we saw with the TREVO 2 data, this technology is helping physicians and patients, and we are very excited to be able to facilitate advances in medical care with game-changing technology like the Trevo Pro Retriever,” said Mark Paul, president of Stryker’s neurovascular division, in a statement.

In its annual shareholder meeting in late April, Curt Hartman, the company’s interim CEO, current chief financial officer and vice president, described stroke as a high-growth segment. He added that the company had entered the complete stroke care market, which it did not play in before, through the $1.5 billion acquisition of the neurovascular business unit of Boston Scientific in 2010 followed by the acquisition of Concentric Medical in August 2011 for $135 million.

“Stroke care is very much in its infancy stages, and the assets that we were able to acquire through the Boston Scientific property and, later, the Concentric acquisition, are two of the market pioneers in this space, and we think will give us long-term growth for many years ahead,” Hartman said, according to Seeking Alpha.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Arundhati Parmar

By Arundhati Parmar

Arundhati Parmar is the Medical Devices Reporter at MedCity News. She has covered medical technology since 2008 and specialized in business journalism since 2001. Parmar has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again.
More posts by Author

0 comments